Journal Article Adoptive immunotherapy for the treatment of glioblastoma: progress and possibilities

Kuramitsu, Shunichiro  ,  Yamamichi, Akane  ,  Ohka, Fumiharu  ,  Motomura, Kazuya  ,  Hara, Masahito  ,  Natsume, Atsushi

8 ( 12 )  , pp.1393 - 1404 , 2016-12 , Future Medicine
Patients with glioblastoma have a very poor prognosis. Adoptive cellular therapy (ACT) is defined as the collection of circulating or tumor-infiltrating lymphocytes, their selection, modification, expansion and activation, and their re-administration to patients in order to induce antitumor activity. Although various ACTs have been attempted, most failed to improve the outcome. Immune checkpoint blockade antibodies and T cell engineering with tumor-specific chimeric antigen receptors suggest the emergence of a new era of immunotherapy. Here, we summarize approaches with ACTs using genetically modified T cells, which have been improved by enhancing their antitumor activity, and discuss strategies to develop these therapies. The mechanisms by which gliomas modulate and evade the immune system are also discussed.

Number of accesses :  

Other information